FDA isn’t done with Aranesp yet.
That, in a nutshell, is what Amgen Inc. had to say about the future of what was once its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?